

## Drug Utilization Review Board Meeting

**December 4, 2014**

| Therapeutic Class                 | Drug Name                       | Current PDL Status | DCH Decisions |
|-----------------------------------|---------------------------------|--------------------|---------------|
| <b>New Drug Reviews</b>           |                                 |                    |               |
| <b>Antihemophillic</b>            |                                 |                    |               |
|                                   | Eloctate<br>(Intravenous) Vial  | NP/PA              | NP/PA         |
| <b>Allergen Immunotherapy</b>     |                                 |                    |               |
|                                   | Grastek (Sublingual)<br>Tablet  | NP/PA              | NP/PA         |
|                                   | Oralair (Sublingual)<br>Tablet  | NP/PA              | NP/PA         |
|                                   | Ragwitek<br>(Sublingual) Tablet | NP/PA              | NP/PA         |
| <b>Lysosomal Storage Disorder</b> |                                 |                    |               |
|                                   | Myalept<br>(Subcutaneous) Vial  | NP/PA              | P/PA          |
| <b>Antineoplastic</b>             |                                 |                    |               |
|                                   | Zykadia (Oral)<br>Capsule       | P/PA               | P/PA          |
| <b>Sedative Hypnotic</b>          |                                 |                    |               |
|                                   | Hetlioz (Oral)<br>Capsule       | NP/PA              | NP/PA         |

PDL=Preferred Drug List; P=preferred; NP=non-preferred; PA=prior authorization

### Class Reviews

#### Sedative Hypnotics

The DUR Board recommended No Changes.

#### Granulocyte Colony Stimulating Factors

The DUR Board recommended No Changes.